Join the Multiple Sclerosis group to help and get support from people like you.
Multiple Sclerosis News (Page 3)
Related terms: MS
Generic Medications Can Keep OOP Costs Down for Neurological Conditions
WEDNESDAY, Oct. 30, 2024 – Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according...
Costs for MS, Parkinson's and Alzheimer's Meds Keep Rising
THURSDAY, Oct. 31, 2024 – A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that same patient spent $2,378 annually, a new report...
What Works Best to Ease MS-Linked Fatigue? New Study Finds Out
FRIDAY, Oct. 25, 2024 – Medication and behavioral therapy are both effective in combatting fatigue caused by multiple sclerosis (MS), either separately or together, a new study finds. MS patients...
Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
FRIDAY, Oct. 25, 2024 – Cognitive behavioral therapy (CBT), modafinil, and their combination are equally beneficial for multiple sclerosis fatigue, according to a study published in the November...
MS Might Raise a Person's Odds for Cancer
THURSDAY, Oct. 10, 2024b – There's a small but significant increased of certain cancers in people battling multiple sclerosis (MS), new research shows. Those malignancies include cancers of the...
Cancer Incidence Increased for People With Multiple Sclerosis
WEDNESDAY, Oct. 9, 2024 – Cancer incidence is increased overall in people with multiple sclerosis (PwMS), with considerable differences depending on cancer type, age, and sex, according to a study...
FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
South San Francisco, CA – September 13, 2024 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has...
European Committee for Treatment and Research in Multiple Sclerosis, Sept. 18-20
The annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis was held from Sept. 18 to 20 in Copenhagen, Denmark, and drew more than 8,500 delegates from around the ...
Aggressive, Early Disease-Modifying Therapy May Slow MS Progression
FRIDAY, Sept. 27, 2024 – Reducing or preventing paramagnetic rim lesions (PRLs) could significantly slow multiple sclerosis (MS) progression, according to a study presented at the annual meeting of...
Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
THURSDAY, Sept. 26, 2024 – For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and...
FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS
THURSDAY, Sept. 26, 2024 – The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection...
Guidelines Provided for Diagnosis of Pediatric, Late-Onset Multiple Sclerosis
TUESDAY, Sept. 24, 2024 – In a clinical review conducted by an international committee of multiple sclerosis (MS) experts in pediatric and adult MS and published online Sept. 16 in JAMA Neurology,...
Initial Symptoms of MS Could Guide Prognosis, Treatment
WEDNESDAY, Sept. 25, 2024 – Two key symptoms that can arise soon after a diagnosis of multiple sclerosis (MS) could predict how swiftly the illness will progress and suggest best treatment options,...
Higher Burden of Comorbidity Linked to Worse Clinical Outcomes in MS
MONDAY, Sept. 23, 2024 – For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according to a study published online Sept. 18 in JAMA...
Some People With MS May Need Earlier, Higher-Dose Meds
WEDNESDAY, Sept. 18, 2024 – Early, aggressive treatment of brain lesions caused by multiple sclerosis could help ward off faster decline in patients, a new study finds. Such treatment could prevent ...
Further information
Related drug support groups
prednisone, methylprednisolone, Medrol, prednisolone, valacyclovir, dexamethasone, Tecfidera, Ocrevus, Gilenya, dimethyl fumarate, Aubagio